Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

Clinical trial NCT07068191 · RECRUITING

Trial details

NCT number: NCT07068191
Sponsor: Phenomen Pharma
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Hepatomegaly Nonalcoholic Fatty Liver (NAFL)Nonalcoholic Fatty Liver Disease (NAFLD)Fatty Liver Fatty Liver, Alcoholic Fatty Liver, Nonalcoholic Fatty Liver Disease

Start date: 2025-06-19
Primary completion: 2025-07-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.